Addex Therapeutics Ltd (CH:ADXN) has released an update.
Addex Therapeutics Ltd has reported significant progress for the year 2023, including the anticipated mid-May 2024 results from their Phase 2 epilepsy study of ADX71149. The company has successfully launched Neurosterix through a partnership with Perceptive Advisors, securing a $63 million Series A funding, which extends their cash runway beyond 2026. Financially, Addex has seen a reduced net loss from CHF 20.8 million in 2022 to CHF 10.6 million in 2023, indicating a stronger fiscal position.
For further insights into CH:ADXN stock, check out TipRanks’ Stock Analysis page.
